Scienture lança REZENOPI, um novo spray nasal de naloxona de 10 mg, para combater overdoses de opiáceos. Scienture launches REZENOPY®, a new 10mg naloxone nasal spray, to combat opioid overdoses.

A Scienture Holdings lançará comercialmente o REZENOPY, um potente spray nasal de naloxona de 10 mg para overdoses de opiáceos, através de um acordo com a Summit Biosciences e a Kindeva Drug Delivery. Scienture Holdings will commercially launch REZENOPY®, a potent 10mg naloxone nasal spray for opioid overdoses, through an agreement with Summit Biosciences and Kindeva Drug Delivery. A Scienture lidará com vendas e marketing, enquanto a Kindeva fabricará a droga. Scienture will handle sales and marketing, while Kindeva will manufacture the drug. Aprovado pela FDA em 2024, o REZENOPY visa ajudar na redução de mortes relacionadas a opióides. Approved by the FDA in 2024, REZENOPY® aims to aid in reducing opioid-related deaths.